AHU-377

Pharmacologic action Novartis’ New Angiomyocardiac LCZ696 Market analysis

Product Name: AHU-377
CAS No.: 149709-62-6
Chemical Name: AHU-377
Synonyms: Sacubitril(AHU-377);Sacubitril API;valsartan/sacubitril Impurity 1;(2R,4S)-5-([1,1'-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid;AHU-37;AHU-77;LCZ697;AHU-377;SACUBRITIL;LCZ-696-007-2S4R
CBNumber: CB62627304
Molecular Formula: C24H29NO5
Formula Weight: 411.49
MOL File: 149709-62-6.mol

More

Less

AHU-377 Property

Boiling point:: 656.9±55.0 °C(Predicted)
Density: 1.151±0.06 g/cm3(Predicted)
storage temp.: Sealed in dry,Store in freezer, under -20°C
solubility: ≥41.1 mg/mL in DMSO; ≥21.45 mg/mL in H2O with ultrasonic; ≥26.85 mg/mL in EtOH with ultrasonic
form: oil
pka: 4.72±0.10(Predicted)
color: colorless

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More

Less

N-Bromosuccinimide Price

TRC

Product number: S080895
Product name: Sacubitril
Packaging: 250mg
Price: $580
Updated: 2021/12/16

TRC

Product number: S080895
Product name: Sacubitril
Packaging: 500mg
Price: $1115
Updated: 2021/12/16

Matrix Scientific

Product number: 132790
Product name: 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoicacid
Purity: 97%
Packaging: 5g
Price: $1980
Updated: 2021/12/16

ApexBio Technology

Product number: B1070
Product name: AHU-377(Sacubitril)
Packaging: 50mg
Price: $885
Updated: 2021/12/16

Matrix Scientific

Product number: 132790
Product name: 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoicacid
Purity: 97%
Packaging: 1g
Price: $648
Updated: 2021/12/16

More

Less

AHU-377 Chemical Properties,Usage,Production

Pharmacologic action

AHU377 and angiotensin IIAT1 receptor antagonist valsartan at a molar ratio of 1: 1 compose LCZ696. LCZ696 was a dual inhibitor of angiotensin II (AT2) receptor and enkephalinase (Neprilysin) receptor. And with its better antihypertensive efficacy than standard antihypertensive drugs, it is a new drug for the treatment of heart failure.
AHU377 is a prodrug that converts the active form of the enzyme cleavage LBQ657 ethyl ester. So far its efficacy and safety in milestone phase III surpass the clinical standard drug enalapril.
In a clinical trial of the drug, 100 to 400 mg of combined drugs, 80 to 320 mg of valsartan, 200 mg of neprilysin inhibition or placebo were given to the patients in the double-blind trial of phase two with mild to moderate hypertension. The combined drugs are more effective and better tolerated with no vascular edema report than solely applied valsartan or other drugs. LCZ696 shows sustainable treatment benefits in the early treatment:
(1) a 20% reduction in the risk of death from cardiovascular disease (p = 0.00004).
(2) hospitalization for heart failure was reduced by 21% (p = 0.00004).
(3) all-cause mortality was reduced by 16% (p = 0.0005).
(4) The overall risk is reduced by 20% according to the composite measure of the primary endpoint of hospitalization for cardiovascular death or heart failure (p = 0.0000002).

Novartis’ New Angiomyocardiac LCZ696

According to a recent study published by Novartis, LCZ696, a cardiovascular drug being developed by the company, will become a new hope for the company. The current study shows that this drug functions well in the remission of cardiovascular necrosis and other symptoms caused by heart disease.
LCZ696 is a combination of Novartis Diovan and AHU-377. Some analysts have spoken highly of the drug and estimated that it might be submitted to the FDA as early as next year. Once confirmed in the audit it will mark another great step forward of Novartis in the field of cardiovascular drugs.
Although it showed high expectations to LCZ696, Novartis still has a long way to go, given the setbacks of its serelaxin in the FDA and the European Medicines Administration.
The news came straight from Basel as investigators around the world were wrapping up the big scientific meeting of the American College of Cardiology.

Market analysis

In the field of research and development of drugs, most of the success of the new drugs in phase II will always lead to a series of competitor projects. The LCZ696 performs so prominently that the industry was shocked. It is predicted that few cardiovascular drugs will be qualified to compete with the LCZ696 in the next few years. Some analysts predict that the LCZ696 sales will peak at $ 8 billion, while Deutsche Bank analysts expect the drug to peak at $ 6 billion, given LCZ696's superior performance in reducing cardiovascular risk. Although the data are slightly different, there is no doubt that, LCZ696 will become a super star to lead the cardiovascular treatment to step into a new era.

Uses

Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug, valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name, Entresto, is a treatment for heart failure.

Definition

ChEBI: Sacubitril is a member of biphenyls.

Biological Activity

ahu-377 is an inhibitor of neprilysin with ic50 value of 5nm [1].ahu-377 and the angiotensin ii at1 receptor antagonist valsartan compose lcz696 in a 1:1 molar ratio. lcz696 is an angiotensin receptor neprilysin inhibitor. it can reduce blood pressure and may be a novel drug for the treatment of heart failure. ahu-377 is a prodrug, it can be converted by enzymatic cleavage of the ethyl ester into the active form lbq657. it is reported that ahu-377(30 and 100 mg/kg, po) can cause antihypertensive effect in a dose-dependent manner in dahl-ss rats. but in the doca-salt hypertensive rats, it shows a weak reduction [2, 3].

target

neprilysin

References

[1] ksander gm, ghai rd, dejesus r, diefenbacher cg, yuan a, berry c, sakane y, trapani a. dicarboxylic acid dipeptide neutral endopeptidase inhibitors. j med chem. 1995 may 12;38(10):1689-700.
[2] voors aa, dorhout b, van der meer p. the potential role of valsartan + ahu377 ( lcz696 ) in the treatment of heart failure. expert opin investig drugs. 2013 aug;22(8):1041-7.
[3] laxminarayan g hegde, cecile yu, cheruvu madhavi et al. comparative efficacy of ahu-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension. bmc pharmacology 2011, 11(suppl 1):p33.

AHU-377 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

AHU-377 Suppliers

China 225 India 10 United Kingdom 2 United States 19 Global 256

Hubei Chenxin Pharmaceutical Co., Ltd.

Tel: 18696113233
Fax: QQ:2544920688
Email: like1076463918@163.com
Country: China
ProdList: 3179
Advantage: 58

Joyochem Co.,Ltd

Tel: 531-82687558 13290333633
Email: sales@joyochem.com
Country: China
ProdList: 19
Advantage: 58

HUBEI HICKS BIOCHEMICAL CO.,LTD

Tel: 18696113233
Email: 15927219311@163.com
Country: China
ProdList: 1617
Advantage: 58

Shanghai Boyle Chemical Co., Ltd.

Tel
Fax: 86-21-57758967
Email: sales@boylechem.com
Country: China
ProdList: 2922
Advantage: 55

ChemFuture PharmaTech (Jiangsu) Ltd

Tel: 5108538618
Fax: 86 510 85386988-8017
Email: suger.wang@chemfuture.com
Country: China
ProdList: 832
Advantage: 65

Beijing HwrkChemical Technology Co., Ltd

Tel: 010-89508211 18501085097
Fax: 010-89508210
Email: sales.bj@hwrkchemical.com
Country: China
ProdList: 8418
Advantage: 55

Jinan Trio PharmaTech Co., Ltd.

Tel: +86 (531) 88811783
Fax: +86 (531) 55696010 QQ 1762738062
Email: sales@trio-pharmatech.com (International market)
Country: China
ProdList: 1856
Advantage: 62

S.Z. PhyStandard Bio-Tech. Co., Ltd.

Tel: 0755-4000505016 13380397412
Fax: 0755 28094224
Email: 3001272453@qq.com
Country: China
ProdList: 5047
Advantage: 50

Haoyuan Chemexpress Co., Ltd.

Tel: 021-58950125
Fax: (86) 21-58955996
Email: info@chemexpress.com
Country: China
ProdList: 7552
Advantage: 61

Moltt Biocem Co., Ltd.

Tel: +86-21-38682181 15900741819
Fax: +86-21-38682181
Country: China
ProdList: 282
Advantage: 55

More

Less

View Lastest Price from AHU-377 manufacturers

BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.

Product: Ahu377 149709-62-6
Price: US $0.00/g
Min. Order: 1g
Purity: More Than 99%
Supply Ability: 50kg/Month
Release date: 2024-09-10

Henan Aochuang Chemical Co.,Ltd.

Product: AHU-377 149709-62-6
Price: US $0.00-0.00/KG
Min. Order: 1KG
Purity: 98%
Supply Ability: 1ton
Release date: 2022-09-29

Hong Kong Tiansheng New Material Trading Co., Ltd

Product: AHU-377 149709-62-6
Price: US $5.99/KG
Min. Order: 1KG
Purity: 99%
Supply Ability: 100KG
Release date: 2021-12-28

149709-62-6, AHU-377Related Search:

Sacubitril Impurity 10 sacubitril (2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoate (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoic acid Valsartan Ethyl (2R,4S)-4-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-4-(2,5-dioxopyrrolidin-1-yl)butanoate LCZ696 interMediate (S)-5-[(Biphenyl-4-yl)carbonyl]pyrrolidin-2-one (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid (2R,4S)-4-([1,1'-Biphenyl]-4-ylmethyl)-2-methyl-4-(2,5-dioxopyrrolidin-1-yl)butanoic acid (2S,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid (R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid LCZ696 (2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoate LCZ Impurity (2R,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid

4-(((2R,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid

AHU-377

4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid

(2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester

(2R,4S)-5-([1,1'-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid

AHU-377,149709-62-6

AHU-37

AHU377; AHU 377; SACUBITRIL

LCZ696(valsartan + sacubitril) impurity 4

AHU-377(Sacubitril)

AHU-377;AHU 377 ;AHU377

AHU-377 (Sacubitril calcium)

4-《(2S,4R)-I-([I,I'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amin

LCZ-696-007-2S4R

valsartan/sacubitril Impurity 1

4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid

4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid

AHU-77

Sacubitril(AHU-377)

(2R,4S)-5-([1,1'-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid (Sacubitril , AHU-377)

LCZ697

4-(((2S,4R)-1-([1,1'-Biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic a

Entresto( sacubitril+ valsartan)

LCZ-696 Impurity 3

(2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic Acid Ethyl Ester

Sacubitril Related Compound 1

[1,1'-Biphenyl]-4-pentanoic acid, γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl-, α-ethyl ester, (αR,γS)-

Sacubitril API

Sacubtril(LCZ696)

Sacubitril Control

SACUBRITIL

AHU-377 USP/EP/BP

Sacubitril Standard

4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxo...

SacubitrilQ: What is Sacubitril Q: What is the CAS Number of Sacubitril Q: What is the storage condition of Sacubitril Q: What are the applications of Sacubitril

[1,1'-Biphenyl]-4-pentanoic acid, γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl-, α-ethyl ester, (αR,γS)-

4-(((2S,4R)-1-([1,1'-Biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid

4-(((2R,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid

149709-62-6

LCZ 696

LCZ696

intermediates

Sacubitril